Read by QxMD icon Read

Prostate Cancer and Prostatic Diseases

Cosimo De Nunzio, Aldo Brassetti, Giuseppe Simone, Riccardo Lombardo, Riccardo Mastroianni, Devis Collura, Giovanni Muto, Michele Gallucci, Andrea Tubaro
The original version of this Article contained an error in the spelling of the authors Cosimo De Nunzio, Aldo Brassetti, Giuseppe Simone, Riccardo Lombardo, Riccardo Mastroianni, Devis Collura, Giovanni Muto, Michele Gallucci and Andrew Tubaro, which were incorrectly given as De Nunzio Cosimo, Brassetti Aldo, Simone Giuseppe, Lombardo Riccardo, Mastroianni Riccardo, Collura Devis, Muto Giovanni, Gallucci Michele and Tubaro Andrea. This has now been corrected in both the PDF and HTML versions of the Article.
February 1, 2019: Prostate Cancer and Prostatic Diseases
Wei Phin Tan, Dimitri Papagiannopoulos, Kalyan C Latchamsetty, Nathaniel Wilson, Nicholas O'Block, Lester Raff, Alfredo Mena Lora, Christopher L Coogan, Michael R Abern
The original version of this article contained an error in the name of author Alfredo Mena Lora. This has now been corrected.
January 31, 2019: Prostate Cancer and Prostatic Diseases
Ville Kukko, Antti Kaipia, Kirsi Talala, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen, Teemu J Murtola
BACKGROUND: Allopurinol reduces oxidative stress and may thus have an anti-inflammatory effect. Previous studies suggest that allopurinol use might decrease the risk of prostate cancer (PCa) among gout patients. We studied the association between allopurinol use and PCa incidence. METHODS: The cohort consists of 76,874 men without prevalent PCa, originally identified for the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). The follow-up started at entry to the trial...
January 29, 2019: Prostate Cancer and Prostatic Diseases
Jui-Ming Liu, Cheng-Ping Yu, Heng-Chang Chuang, Chun-Te Wu, Ren-Jun Hsu
BACKGROUND: Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases. METHODS: We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox proportional hazards models with 1:1 propensity score-matched analysis were used to investigate the association between ADT use and the risk of autoimmune diseases...
January 28, 2019: Prostate Cancer and Prostatic Diseases
Esther A Boudewijns, Lisette Nieuwenhuis, Milan S Geybels, Piet A van den Brandt
BACKGROUND: The consumption of nuts has been associated with a reduction of cancer risk, but only a few studies have examined the effects of nuts on prostate cancer risk. The current study prospectively investigated the association between the consumption of total nuts, tree nuts, peanuts, and peanut butter and the risk of total, advanced, and non-advanced prostate cancer. METHODS: The association between nuts and prostate cancer was evaluated in the Netherlands Cohort Study, which was conducted among 58,279 men aged 55-69 year at baseline...
January 28, 2019: Prostate Cancer and Prostatic Diseases
Teemu J Murtola, Samueli M Sälli, Kirsi Talala, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen
INTRODUCTION: Diabetes mellitus has been linked with adverse prostate cancer (PCa) outcomes. However, role of hyperglycemia in PCa progression is unclear. We evaluated the link between hyperglycemia and PCa survival among Finnish PCa patients. METHODS: The study cohort included 1770 men with data on fasting glucose and diagnosed with PCa within the Finnish Randomized Study of Screening for PCa in 1995-2009. Additionally, 1398 men had data on glycated hemoglobin (HbA1c)...
January 24, 2019: Prostate Cancer and Prostatic Diseases
Min-Jin Lee, Dong-Ah Park, Seon Heui Lee
BACKGROUND: This study presented the utility across approaches (robotic-assisted radical prostatectomy (RARP) and laparoscopic radical prostatectomy (LRP) or open radical prostatectomy (ORP)), across disease states after surgery, and also across functional outcomes for localized prostate cancers. The utility was measured using the time trade-off method. METHODS: This survey was based on a scenario that describes the state of health in detail and considers surgical methods, short-term adverse effects following RP, disease-specific conditions, and additional treatments 1 year following RP...
January 24, 2019: Prostate Cancer and Prostatic Diseases
Stephen J Freedland, Lauren Howard, Jenifer Allen, Jordan Smith, Jennifer Stout, William Aronson, Brant A Inman, Andrew J Armstrong, Daniel George, Eric Westman, Pao-Hwa Lin
PURPOSE: The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances. MATERIALS AND METHODS: This randomized multi-center trial of prostate cancer (PCa) patients initiating ADT was designed to compare an LCD (≤20g carbohydrate/day) plus walking (≥30 min for ≥5 days/week) intervention vs. control advised to maintain usual diet and exercise patterns. Primary outcome was change in insulin resistance by homeostatic model assessment at 6 months...
January 21, 2019: Prostate Cancer and Prostatic Diseases
Anouck Kluytmans, Jurgen J Fütterer, Mark Emberton, Michiel Sedelaar, Janneke Grutters
Focal therapy (FT) for the treatment of localized prostate cancer offers an alternative strategy for men seeking active treatment. Although relatively new, existing studies suggest that the majority of men who undergo FT tend to maintain levels of genito-urinary function that are indistinguishable from their pre-treatment status. However, as part of the shared decision making process, men need to balance good tolerability against a greater risk of recurrence given that much of the prostate remains intact after FT...
January 21, 2019: Prostate Cancer and Prostatic Diseases
Lisa F Newcomb, Yingye Zheng, Anna V Faino, Daniella Bianchi-Frias, Matthew R Cooperberg, Marshall D Brown, James D Brooks, Atreya Dash, Michael D Fabrizio, Martin E Gleave, Michael Liss, Todd M Morgan, Ian M Thompson, Andrew A Wagner, Peter R Carroll, Peter S Nelson, Daniel W Lin
BACKGROUND: For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. This study examined the association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification. METHODS: Urine was collected at baseline, 6, 12, and 24 months in the multi-institutional Canary Prostate Active Surveillance Study (PASS), and PCA3 and T2:ERG levels were quantitated. Reclassification was an increase in Gleason score or ratio of biopsy cores with cancer to ≥34%...
January 21, 2019: Prostate Cancer and Prostatic Diseases
Shaheen Alanee, Ahmed El-Zawahry, Danuta Dynda, Kevin McVary, Mallory Karr, Andrea Braundmeier-Fleming
OBJECTIVES: To prospectively examine the changes in microbiota within the urinary tract after transrectal prostate biopsy. MATERIALS AND METHODS: Data, urine, and fecal samples prospectively collected from 30 patients before and after transrectal biopsy of the prostate. DNA was extracted from urine collected after a prostate massage before and after prostate biopsy, and from fecal samples collected before the biopsy. We sequenced DNA using the bacterial 16S rRNA high-throughput next-generation sequencing and analyzed changes in microbial profiles for taxonomy comparison between samples...
January 21, 2019: Prostate Cancer and Prostatic Diseases
Donald L Bliwise
No abstract text is available yet for this article.
January 17, 2019: Prostate Cancer and Prostatic Diseases
Jillian N Eskra, Daniel Rabizadeh, Christian P Pavlovich, William J Catalona, Jun Luo
BACKGROUND: Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, prognosis, disease monitoring, and prediction of treatment efficacy. In this review, we focus on important advances as well as future efforts needed to drive clinical innovation in this area of urine biomarker research for prostate cancer detection and prognostication...
January 17, 2019: Prostate Cancer and Prostatic Diseases
Saher Zaidi, Jason Gandhi, Gunjan Joshi, Noel L Smith, Sardar Ali Khan
BACKGROUND: Prostate cancer (PCa) is characterized as the most frequent type of cancer in males. Recent research has suggested patients who have diabetes mellitus taking metformin (MF) have a lower risk of PCa. MF has antineoplastic effects such as adenosine monophosphate-activated protein kinase (AMPK)-dependent and independent mechanisms, suppression of androgen signaling pathway, and alterations of insulin-like growth factor-1 (IGF-1) signaling pathways that cause the growth and proliferation of PCa...
January 16, 2019: Prostate Cancer and Prostatic Diseases
Edoardo Francini, Kathryn P Gray, Grace K Shaw, Carolyn P Evan, Anis A Hamid, Caitlin E Perry, Philip W Kantoff, Mary-Ellen Taplin, Christopher J Sweeney
BACKGROUND: In 2004, docetaxel was shown to prolong the overall survival (OS) of patients with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new systemic therapies have been shown to prolong OS in men with mCRPC. We sought to evaluate the aggregate impact of these newer therapies on the OS of patients with mCRPC. METHODS: Two cohorts of patients diagnosed with mCRPC between 2004 and 2007, treated with drugs used in the limited treatment era only (A), and between 2010 and 2013, treated also with newer therapies (B), were identified from the Dana-Farber Cancer Institute database...
January 14, 2019: Prostate Cancer and Prostatic Diseases
Daniel Rukstalis, Douglas Grier, Sean Stroup, Ronald Tutrone, Euclid deSouza, Sheldon Freedman, Richard David, Jed Kamientsky, Gregg Eure
Evidence indicating Prostatic Urethral Lift (PUL) delivers significant improvement in symptomatic BPH with low morbidity is based on subjects with lateral lobe (LL) enlargement only. MedLift was an FDA IDE extension of the L.I.F.T. randomized study designed to examine safety and efficacy of PUL for treatment of obstructive middle lobes (OML). Inclusion criteria for this non-randomized cohort were identical to the L.I.F.T. randomized study, except for requiring an OML: ≥ 50 years of age, IPSS ≥ 13, and Qmax ≤ 12 ml/s...
December 12, 2018: Prostate Cancer and Prostatic Diseases
Hyung L Kim, Ping Li, Huei-Chung Huang, Samineh Deheshi, Tara Marti, Beatrice Knudsen, Hatem Abou-Ouf, Ridwan Alam, Tamara L Lotan, Lucia L C Lam, Marguerite du Plessis, Elai Davicioni, Neil Fleshner, Brian R Lane, Ashley E Ross, John W Davis, James L Mohler, Bruce J Trock, Eric A Klein, Jeffrey J Tosoian, M Eric Hyndman, Tarek A Bismar
ABSTACT: BACKGROUND: Many men diagnosed with prostate cancer are active surveillance (AS) candidates. However, AS may be associated with increased risk of disease progression and metastasis due to delayed therapy. Genomic classifiers, e.g., Decipher, may allow better risk-stratify newly diagnosed prostate cancers for AS. METHODS: Decipher was initially assessed in a prospective cohort of prostatectomies to explore the correlation with clinically meaningful biologic characteristics and then assessed in diagnostic biopsies from a retrospective multicenter cohort of 266 men with National Comprehensive Cancer Network (NCCN) very low/low and favorable-intermediate risk prostate cancer...
December 12, 2018: Prostate Cancer and Prostatic Diseases
Gyorgy Petrovics, Douglas K Price, Hong Lou, Yongmei Chen, Lisa Garland, Sara Bass, Kristine Jones, Indu Kohaar, Amina Ali, Lakshmi Ravindranath, Denise Young, Jennifer Cullen, Tiffany H Dorsey, Isabell A Sesterhenn, Stephen A Brassell, Inger L Rosner, Doug Ross, William Dahut, Stefan Ambs, William Douglas Figg, Shiv Srivastava, Michael Dean
BACKGROUND: Germline mutations in BRCA2 have been linked to a higher risk of prostate cancer (PCa), and high frequency of BRCA1 and BRCA2 (BRCA1/2) gene alterations was recently reported in metastatic castration-resistant PCa specimens. Mutations in BRCA2 vary in racial and ethnic groups including African-American (AA) and Caucasian-American (CA) populations. METHODS: BRCA1 and BRCA2 genes were sequenced (Ion AmpliSeq targeted sequencing) in archived blood DNA specimens in 1240 PCa patients, including 30% AA patients, in three different cohorts: localized early stage (T2) PCa (N = 935); advanced PCa (50% T3-4) (N = 189); and metastatic PCa (N = 116)...
December 12, 2018: Prostate Cancer and Prostatic Diseases
Ding-Wei Ye, Yao Zhu
No abstract text is available yet for this article.
December 5, 2018: Prostate Cancer and Prostatic Diseases
Fredrik Jäderling, Olof Akre, Markus Aly, Johan Björklund, Mats Olsson, Christofer Adding, Michael Öberg, Lennart Blomqvist, Tommy Nyberg, Peter Wiklund, Stefan Carlsson
BACKGROUND: It is unclear whether preoperative staging using Magnetic Resonance Imaging (MRI) reduces the risk of positive margins in prostate cancer. We aimed to assess the effect on surgical margins and degree of nerve sparing of a pelvic MRI presented at a preoperative MRI conference. METHODS: Single institution, observational cohort study including 1037 men that underwent robot assisted radical prostatectomy between October 2013 and June 2015. Of these, 557 underwent a preoperative MRI combined with a preoperative MRI conference and 410 did not...
November 30, 2018: Prostate Cancer and Prostatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"